Previous Close | 42.20 |
Open | 42.14 |
Bid | 42.12 x 1400 |
Ask | 42.20 x 800 |
Day's Range | 42.15 - 42.21 |
52 Week Range | 24.69 - 45.76 |
Volume | |
Avg. Volume | 46,030 |
Market Cap | 1.586B |
Beta (5Y Monthly) | 0.61 |
PE Ratio (TTM) | 34.59 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Dec 10, 2018 |
1y Target Est | N/A |
Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.
Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.
The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.